Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05661461 · ClinicalTrials.gov registry record · Phase 1
Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment
A Phase 1 study of Advanced Solid Tumor and Tumor, sponsored by Aadi Bioscience.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 2
- Study locations
NCT05661461 is a Phase 1 study of Advanced Solid Tumor and Tumor that is actively recruiting participants, run by Aadi Bioscience. The registered enrollment target is 28 participants, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (85% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05661461, a Phase 1 study of Advanced Solid Tumor and Tumor, is actively recruiting participants, sponsored by Aadi Bioscience.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a phase 1, multi-center, open-label, dose-escalation study of nab-sirolimus in adult patients with locally advanced or metastatic solid tumors and moderate hepatic impairment or normal hepatic function.
Conditions Studied
Interventions
- DRUG nab-sirolimus
Study Locations (2)
Texas
- South Texas Accelerated Research Therapeutics, LLC - San Antonio
Utah
- START Mountain Region - West Valley City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2022-11-23 |
| Est. Completion | 2026-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05661461
The ClinicalTrials.gov registry entry for NCT05661461 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (85% lower). The listed sponsor is Aadi Bioscience, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which nab-sirolimus is the first listed.
NCT05661461 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Texas, Utah.
Frequently Asked Questions
What is clinical trial NCT05661461 about?
NCT05661461 is a clinical study titled "Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment". This is a phase 1, multi-center, open-label, dose-escalation study of nab-sirolimus in adult patients with locally advanced or metastatic solid tumors and moderate hepatic impairment or normal hepatic function.
What is the current status of trial NCT05661461?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2022-11-23. Estimated completion is 2026-08-01.
What conditions does trial NCT05661461 study?
This clinical trial studies the following conditions: Advanced Solid Tumor, Tumor, Tumor, Solid.
What interventions are being tested in trial NCT05661461?
The interventions under investigation include: nab-sirolimus (DRUG).
Who is sponsoring clinical trial NCT05661461?
This trial is sponsored by Aadi Bioscience, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05661461 being conducted?
This trial has 2 study locations across Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.